Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: A saccadic eye movement study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1753-1764

  Babin, Shelly L ^a   Hood, Ashley J ^a   Wassef, Adel A ^b   Williams, Nina G ^a   Patel, Saumil S ^a   Sereno, Anne B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cognitive control; Neuropsychological test; Saccades; Schizophrenia; Typical antipsychotic

Indexed keywords

BENZATROPINE; DIPHENHYDRAMINE; ENALAPRIL; FLUPHENAZINE; HALOPERIDOL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LORAZEPAM; METFORMIN; PARACETAMOL; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; LATENT PERIOD; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PSYCHOLOGIC ASSESSMENT; SACCADIC EYE MOVEMENT; SCHIZOPHRENIA; STROOP TASK AND THE POSITIVE AND NEGATIVE SYNDROME SCALE; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; FEMALE; HALOPERIDOL; HUMANS; INPATIENTS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SACCADES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79961127189     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.06.004     Document Type: Article

References (78)

1. Bechard-Evans L., Iyer S., Lepage M., Joober R., Malla A. Investigating cognitive deficits and symptomatology across pre-morbid adjustment patterns in first-episode psychosis. Psychol Med 2010, 40(5):749-759.
2. Broerse A., Holthausen E.A., van den Bosch R.J., den Boer J.A. Does frontal normality exist in schizophrenia? A saccadic eye movement study. Psychiatry Res 2001, 103(2-3):167-178.
3. Brozoski T.J., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979, 205(4409):929-932.
4. Cassady S.L., Thaker G.K., Tamminga C.A. Pharmacologic relationship of antisaccade and dyskinesia in schizophrenic patients. Psychopharmacol Bull 1993, 29(2):235-240.
5. Cassens G., Inglis A.K., Appelbaum P.S., Gutheil T.G. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990, 16(3):477-499.
6. Chudasama Y., Robbins T.W. Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex. Neuropsychopharmacology 2004, 29(9):1628-1636.
7. Cleghorn J.M., Kaplan R.D., Szechtman B., Szechtman H., Brown G.M. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res 1990, 3(3):211-219.
8. Crawford T.J., Haeger B., Kennard C., Reveley M.A., Henderson L. Saccadic abnormalities in psychotic patients. II. The role of neuroleptic treatment. Psychol Med 1995, 25(3):473-483.
9. Eichelbaum M., Ingelman-Sundberg M., Evans W.E. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006, 57:119-137.
10. Ettinger U., Kumari V., Crawford T.J., Davis R.E., Sharma T., Corr P.J. Reliability of smooth pursuit, fixation, and saccadic eye movements. Psychophysiology 2003, 40(4):620-628.
11. Fukushima J., Fukushima K., Chiba T., Tanaka S., Yamashita I., Kato M. Disturbances of voluntary control of saccadic eye movements in schizophrenic patients. Biol Psychiatry 1988, 23(7):670-677.
12. Funahashi S., Bruce C.J., Goldman-Rakic P.S. Neuronal activity related to saccadic eye movements in the monkey's dorsolateral prefrontal cortex. J Neurophysiol 1991, 65(6):1464-1483.
13. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000, 321(7273):1371-1376.
14. Goldman-Rakic P.S. Psychopathology and the Brain 1991, Raven, New York.
15. Goldman-Rakic P.S., Muly E.C., Williams G.V. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000, 31(2-3):295-301.
16. Gonzalez-Blanch C., Rodriguez-Sanchez J.M., Perez-Iglesias R., Pardo-Garcia G., Martinez-Garcia O., Vazquez-Barquero J.L., et al. First-episode schizophrenia patients neuropsychologically within the normal limits: evidence of deterioration in speed of processing. Schizophr Res 2010, 119(1-3):18-26.
17. Gooding D.C., Basso M.A. The tell-tale tasks: a review of saccadic research in psychiatric patient populations. Brain Cogn 2008, 68(3):371-390.
18. Gooding D.C., Mohapatra L., Shea H.B. Temporal stability of saccadic task performance in schizophrenia and bipolar patients. Psychol Med 2004, 34(5):921-932.
19. Granon S., Passetti F., Thomas K.L., Dalley J.W., Everitt B.J., Robbins T.W. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 2000, 20(3):1208-1215.
20. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153(3):321-330.
21. Guitton D., Buchtel H.A., Douglas R.M. Frontal lobe lesions in man cause difficulties in suppressing reflexive glances and in generating goal-directed saccades. Exp Brain Res 1985, 58(3):455-472.
22. Harris M.S., Reilly J.L., Keshavan M.S., Sweeney J.A. Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia. Psychol Med 2006, 36(4):485-494.
23. Harvey P.D., Howanitz E., Parrella M., White L., Davidson M., Mohs R.C., et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 1998, 155(8):1080-1086.
24. Harvey P.D., Rabinowitz J., Eerdekens M., Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005, 162(10):1888-1895.
25. Hogarty G.E., Ulrich R.F. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998, 32(3-4):243-250.
26. Holzman P.S., Proctor L.R., Hughes D.W. Eye-tracking patterns in schizophrenia. Science 1973, 181(95):179-181.
27. Holzman P.S., Proctor L.R., Levy D.L., Yasillo N.J., Meltzer H.Y., Hurt S.W. Eye-tracking dysfunctions in schizophrenic patients and their relatives. Arch Gen Psychiatry 1974, 31(2):143-151.
28. Hori H., Noguchi H., Hashimoto R., Nakabayashi T., Omori M., Takahashi S., et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006, 86(1-3):138-146.
29. Hu X.T., Wang R.Y. Comparison of effects of D-1 and D-2 dopamine receptor agonists on neurons in the rat caudate putamen: an electrophysiological study. J Neurosci 1988, 8(11):4340-4348.
30. Hu X.T., White F.J. Dopamine enhances glutamate-induced excitation of rat striatal neurons by cooperative activation of D1 and D2 class receptors. Neurosci Lett 1997, 224(1):61-65.
31. Hutton S.B., Ettinger U. The antisaccade task as a research tool in psychopathology: a critical review. Psychophysiology 2006, 43(3):302-313.
32. Hutton S.B., Crawford T.J., Puri B.K., Duncan L.J., Chapman M., Kennard C., et al. Smooth pursuit and saccadic abnormalities in first-episode schizophrenia. Psychol Med 1998, 28(3):685-692.
33. Kawai N., Yamakawa Y., Baba A., Nemoto K., Tachikawa H., Hori T., et al. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(6):1009-1014.
34. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
35. Keefe R.S., Young C.A., Rock S.L., Purdon S.E., Gold J.M., Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006, 81(1):1-15.
36. Kern R.S., Glynn S.M., Horan W.P., Marder S.R. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull 2009, 35(2):347-361.
37. Larrison-Faucher A.L., Matorin A.A., Sereno A.B. Nicotine reduces antisaccade errors in task impaired schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28(3):505-516.
38. Leigh R.J., Kennard C. Using saccades as a research tool in the clinical neurosciences. Brain 2004, 127(Pt 3):460-477.
39. Levy D.L., Holzman P.S., Matthysse S., Mendell N.R. Eye tracking and schizophrenia: a selective review. Schizophr Bull 1994, 20(1):47-62.
40. Lidow M.S., Goldman-Rakic P.S. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci U S A 1994, 91(10):4353-4356.
41. Lidow M.S., Elsworth J.D., Goldman-Rakic P.S. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther 1997, 281(1):597-603.
42. Lustig C., Meck W.H. Chronic treatment with haloperidol induces deficits in working memory and feedback effects of interval timing. Brain Cogn 2005, 58(1):9-16.
43. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999, 25(2):233-255.
44. Mishara A.L., Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004, 55(10):1013-1022.
45. Mortimer A.M. Cognitive function in schizophrenia - do neuroleptics make a difference?. Pharmacol Biochem Behav 1997, 56(4):789-795.
46. Muller N., Riedel M., Eggert T., Straube A. Internally and externally guided voluntary saccades in unmedicated and medicated schizophrenic patients. Part II. Saccadic latency, gain, and fixation suppression errors. Eur Arch Psychiatry Clin Neurosci 1999, 249(1):7-14.
47. Munoz D.P., Everling S. Look away: the anti-saccade task and the voluntary control of eye movement. Nat Rev Neurosci 2004, 5(3):218-228.
48. Nasrallah H.A., Targum S.D., Tandon R., McCombs J.S., Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv 2005, 56(3):273-282.
49. Nicola S.M., Surmeier J., Malenka R.C. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 2000, 23:185-215.
50. Nisenbaum E.S., Orr W.B., Berger T.W. Evidence for two functionally distinct subpopulations of neurons within the rat striatum. J Neurosci 1988, 8(11):4138-4150.
51. Pierrot-Deseilligny C., Muri R.M., Nyffeler T., Milea D. The role of the human dorsolateral prefrontal cortex in ocular motor behavior. Ann N Y Acad Sci 2005, 1039:239-251.
52. Pigache R.M. The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine. Schizophr Res 1993, 10(1):39-50.
53. Ploner C.J., Gaymard B.M., Rivaud-Pechoux S., Pierrot-Deseilligny C. The prefrontal substrate of reflexive saccade inhibition in humans. Biol Psychiatry 2005, 57(10):1159-1165.
54. Purdon S.E., Malla A., Labelle A., Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001, 26(2):137-149.
55. Radant A.D., Dobie D.J., Calkins M.E., Olincy A., Braff D.L., Cadenhead K.S., et al. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res 2007, 89(1-3):320-329.
56. Reilly J.L., Lencer R., Bishop J.R., Keedy S., Sweeney J.A. Pharmacological treatment effects on eye movement control. Brain Cogn 2008, 68(3):415-435.
57. Remillard S., Pourcher E., Cohen H. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophr Res 2005, 80(1):99-106.
58. Riccardi P., Zald D., Li R., Park S., Ansari M.S., Dawant B., et al. Sex differences in amphetamine-induced displacement of [(18)F]fallypride in striatal and extrastriatal regions: a PET study. Am J Psychiatry 2006, 163(9):1639-1641.
59. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999, 156(4):544-549.
60. Ross D.E. The deficit syndrome and eye tracking disorder may reflect a distinct subtype within the syndrome of schizophrenia. Schizophr Bull 2000, 26(4):855-866.
61. Saeedi H., Remington G., Christensen B.K. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 2006, 85(1-3):222-231.
62. Sawaguchi T., Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991, 251(4996):947-950.
63. Seidman L.J., Pepple J.R., Faraone S.V., Kremen W.S., Green A.I., Brown W.A., et al. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry 1993, 33(8-9):575-584.
64. Sereno A.B. Parsing cognitive processes: psychopathological and neurophysiological constraints. Psychopathology: The Evolving Science of Mental Disorder 1996, 407-432. Cambridge University Press, New York. S. Matthysse, D.L. Levy, J. Kagan, F.M. Benes (Eds.).
65. Sereno A.B., Holzman P.S. Express saccades and smooth pursuit eye movement function in schizophrenic, affective disorder and normal subjects. J Cogn Neurosci 1993, 5:303-316.
66. Sereno A.B., Holzman P.S. Antisaccades and smooth pursuit eye movements in schizophrenia. Biol Psychiatry 1995, 37(6):394-401.
67. Sereno A.B., Briand K.A., Amador S.C., Szapiel S.V. Disruption of reflexive attention and eye movements in an individual with a collicular lesion. J Clin Exp Neuropsychol 2006, 28(1):145-166.
68. Shen R.Y., Asdourian D., Chiodo L.A. Microiontophoretic studies of the effects of D-1 and D-2 receptor agonists on type I caudate nucleus neurons: lack of synergistic interaction. Synapse 1992, 11(4):319-329.
69. Stroop J.R. Studies of interference in serial verbal reactions. J Exp Psychol 1935, 12:643-662.
70. Sweeney J.A., Bauer K.S., Keshavan M.S., Haas G.L., Schooler N.R., Kroboth P.D. Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients. Neuropsychopharmacology 1997, 16(3):217-228.
71. Sweeney J.A., Levy D., Harris M.S. Commentary: eye movement research with clinical populations. Prog Brain Res 2002, 140:507-522.
72. Velligan D.I., Newcomer J., Pultz J., Csernansky J., Hoff A.L., Mahurin R., et al. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophr Res 2002, 53(3):239-248.
73. Verdoux H., Magnin E., Bourgeois M. Neuroleptic effects on neuropsychological test performance in schizophrenia. Schizophr Res 1995, 14(2):133-139.
74. Waterworth D.M., Bassett A.S., Brzustowicz L.M. Recent advances in the genetics of schizophrenia. Cell Mol Life Sci 2002, 59(2):331-348.
75. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376(6541):572-575.
76. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007, 89(1-3):211-224.
77. Wu E.Q., Birnbaum H.G., Shi L., Ball D.E., Kessler R.C., Moulis M., et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005, 66(9):1122-1129.
78. Zanelli J., Simon H., Rabe-Hesketh S., Walshe M., McDonald C., Murray R.M., et al. Eye tracking in schizophrenia: does the antisaccade task measure anything that the smooth pursuit task does not?. Psychiatry Res 2005, 136(2-3):181-188.